Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro

Long-circulating liposomes loaded with doxorubicin (Dox) were additionally modified with the prostate cell-specific monoclonal antibody 5D4 (mAb 5D4). The resultant Dox-loaded 5D4-immunoliposomes specifically recognized prostate cancer cell lines of several different types expressing the mAb 5D4 ant...

Full description

Saved in:
Bibliographic Details
Published in:Journal of drug targeting 2008-01, Vol.16 (7-8), p.601-604
Main Authors: Sawant, Rishikesh M., Cohen, Michael B., Torchilin, Vladimir P., Rokhlin, Oskar W.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - administration & dosage
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cell Line, Tumor
Doxorubicin - administration & dosage
Doxorubicin - therapeutic use
Drug Carriers
Drug Delivery Systems
General pharmacology
Humans
Liposomes
Male
Medical sciences
Particle Size
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Prostatic Neoplasms - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long-circulating liposomes loaded with doxorubicin (Dox) were additionally modified with the prostate cell-specific monoclonal antibody 5D4 (mAb 5D4). The resultant Dox-loaded 5D4-immunoliposomes specifically recognized prostate cancer cell lines of several different types expressing the mAb 5D4 antigen, PSMA, and significantly enhanced cytotoxicity toward these cells compared with the non-targeted Dox-liposomes in vitro while no increased toxicity was observed toward non-prostate (lung) cancer cell line.
ISSN:1061-186X
1029-2330
DOI:10.1080/10611860802228954